NCT07635043Not yet recruitingPhase 4
Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 3 Jun 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Pakistan Institute of Medical Sciences
- Diseases
- Psoriasis
- NCT number
- NCT07635043
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Aug 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe psoriasis (BSA \>20% or requiring systemic therapy)
- Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
- Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment
- Use of powerful topical corticosteroids within two weeks previously
Other illness
- Known hypersensitivity to Tapinarof or any of its excipients
- History of malignancy or current active infection
- Known hypersensitivity to betamethasone or Tapinarof
Other
- Pregnant and lactating mothers
Who the study is looking for
- Age 18 years-65 years
- Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
- Disease duration of at least 6 months
- Willing and able to provide written informed consent
- Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pakistan institute of medical sciences(PIMS) Coordinator of this site? Confirm its status | Islamabad | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.